MTOR and ovarian carcinoma: Activated mTOR signaling can trigger epithelial–mesenchymal transition (EMT) and promote the maintenance of cancer stem cells (CSCs), resulting in chemoresistance in ovarian cancer patients, and treatment with BEZ235 (a dual PI3K/mTOR inhibitor) might be a promising approach for reversing chemoresistance [112].